{"disease":{"id":"pre-term","name":"pre term"},"drugs":{"marketed":[{"drug_id":"progesterone-plus-hcg","indication_name":"Pregnancy termination","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Progesterone","generic_name":"Progesterone plus HCG","company_name":"Dunamenti REK Istenhegyi IVF Center","drug_phase":"marketed","molecular_target":"progesterone receptor, luteinizing hormone/choriogonadotropin receptor","drug_class":"Progesterone [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score (TPS) ≥ 50%) as monotherapy (pembrolizumab in combination with pemetrexed and platinum (pemetrexed + platinum) in patients with a PD-L1 TPS ≥ 1% as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"obe001","indication_name":"Preterm labor (delay of preterm birth)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OBE001","company_name":"ObsEva SA","drug_phase":"discontinued","molecular_target":"Oxytocin receptor (OXTR)","drug_class":"Oxytocin receptor antagonist; Tocolytic agent","quality_score":null,"revenue":null,"mechanism":"OBE001 is an oxytocin receptor antagonist that inhibits uterine contractions by blocking oxytocin signaling in myometrial smooth muscle."}],"offLabel":[],"totalMarketed":58,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03112018","title":"Strengthening Facility-based Intrapartum/Immediate Newborn Care to Reduce Mortality of Preterm Infants in Migori County, Kenya and Busoga Region, Uganda","phase":"NA","overall_status":"COMPLETED","enrollment_count":102988,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06461429","title":"PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"University of Melbourne","has_results":false},{"nct_id":"NCT04182503","title":"Environmental Factors and Embryonic Development Project","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Jinling Hospital, China","has_results":false},{"nct_id":"NCT02986802","title":"Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":89132,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT05087160","title":"Socioeconomic Inequalities Exacerbated by Mitigation Measures to COVID-19 and Differences in Prematurity Prevalence","phase":"","overall_status":"COMPLETED","enrollment_count":37323,"lead_sponsor_name":"Universidad de la Republica","has_results":false},{"nct_id":"NCT00339235","title":"Establishment of a Perinatal Database and a Bank of Biological Materials","phase":"","overall_status":"COMPLETED","enrollment_count":30570,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT03154177","title":"Group Antenatal/Postnatal Care in Rwanda","phase":"NA","overall_status":"COMPLETED","enrollment_count":26381,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06653374","title":"Perinatal Conditions Influencing Morbidity, Mortality, and Medical Care in Newborns","phase":"","overall_status":"COMPLETED","enrollment_count":26000,"lead_sponsor_name":"HOSPITAL GINECO OBSTETRICO ISIDRO AYORA","has_results":false},{"nct_id":"NCT07212751","title":"Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT00340249","title":"Use of the Perinatal Database and Biologic Tissue Bank at The Perinatology Research Branch (PRB)","phase":"","overall_status":"COMPLETED","enrollment_count":20964,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT06664554","title":"Predictive Value of Maternal Blood Protein Signatures in Preterm Birth","phase":"","overall_status":"COMPLETED","enrollment_count":18000,"lead_sponsor_name":"HBI Solutions Inc.","has_results":false},{"nct_id":"NCT05131282","title":"Maternal Serum Markers Predicting Preeclampsia At Early Gestations","phase":"","overall_status":"COMPLETED","enrollment_count":18000,"lead_sponsor_name":"HBI Solutions Inc.","has_results":false},{"nct_id":"NCT06955728","title":"A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":13000,"lead_sponsor_name":"University of Witwatersrand, South Africa","has_results":false},{"nct_id":"NCT05502510","title":"Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application","phase":"","overall_status":"COMPLETED","enrollment_count":12344,"lead_sponsor_name":"Naima Health LLC","has_results":false},{"nct_id":"NCT03923023","title":"Impact of the PREEMI Package on Neonatal Mortality","phase":"","overall_status":"COMPLETED","enrollment_count":11195,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT02333227","title":"Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi","phase":"NA","overall_status":"COMPLETED","enrollment_count":10069,"lead_sponsor_name":"Baylor College of Medicine","has_results":true},{"nct_id":"NCT06074601","title":"MIRACLE of LIFE Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Mirvie","has_results":false},{"nct_id":"NCT03921177","title":"Micronutrient Supplementation Before and During 1st Pregnancy to Improve Birth Outcomes (JiVitA-5)","phase":"NA","overall_status":"TERMINATED","enrollment_count":9859,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT05073978","title":"B-vitamin Levels and Adverse Pregnancy Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":7500,"lead_sponsor_name":"Westlake University","has_results":false},{"nct_id":"NCT00342277","title":"Microarray Expression Profiling to Identify Stereotypic mRNA Profiles in Human Parturition","phase":"","overall_status":"COMPLETED","enrollment_count":6838,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT02288832","title":"Medico-economic Impact of Screening Atopobium Vaginae and Gardnerella Vaginalis in Molecular Biology by \"Point-of-care\" During Pregnancy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":6800,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT06125860","title":"BEP Targeting Strategies in Ethiopia","phase":"NA","overall_status":"RECRUITING","enrollment_count":6750,"lead_sponsor_name":"Harvard School of Public Health (HSPH)","has_results":false},{"nct_id":"NCT04301518","title":"Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6500,"lead_sponsor_name":"Sera Prognostics, Inc.","has_results":false},{"nct_id":"NCT06957769","title":"Biological Impacts of Rising Temperatures on Maternal, Fetal, and Newborn Health: A Cohort Study (BIRTH Cohort)","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Aga Khan University","has_results":false},{"nct_id":"NCT07424846","title":"Xylitol and the Prevention of Periodontal Disease and Preterm Birth Trial","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT07238231","title":"Taiwan Preterm Infant Database: Analysis and Comparison of Birth Conditions and Exploration of Prognostic Factors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03360539","title":"Nurse-Family Partnership Impact Evaluation in South Carolina","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5670,"lead_sponsor_name":"Harvard School of Public Health (HSPH)","has_results":true},{"nct_id":"NCT03814395","title":"Peking University Birth Cohort in Tongzhou","phase":"","overall_status":"UNKNOWN","enrollment_count":5426,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06720363","title":"Development of a Predictive Model of Fetal PH At Birth from Novel Variables Derived from Cardiotocographic Tracing","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03974724","title":"Preterm Birth Prediction by Measurement of Biomarkers in Cervical Vaginal Fluid","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03668327","title":"Preterm Birth Cohort Study in Guangzhou","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT00342667","title":"Clinical, Biochemical, Histological and Biophysical Parameters in the Prediction of Cerebral Palsy in Patients With Preterm Labor and Premature Rupture of Membranes","phase":"","overall_status":"COMPLETED","enrollment_count":4673,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT03271723","title":"The 2015 Pelotas (Brazil) Birth Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":4275,"lead_sponsor_name":"Federal University of Pelotas","has_results":false},{"nct_id":"NCT04433364","title":"COPE - COVID-19 in Pregnancy and Early Childhood","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3834,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT04413019","title":"Domiciliary Versus Hospital Management of PPROM","phase":"","overall_status":"COMPLETED","enrollment_count":3662,"lead_sponsor_name":"Ahmed Mohammed Selim","has_results":false},{"nct_id":"NCT00340002","title":"Fetal Anatomy by Three-Dimensional Ultrasound","phase":"","overall_status":"COMPLETED","enrollment_count":3650,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT03078439","title":"EPIPAGE2 Cohort Study Follow up at Five and a Half Years","phase":"","overall_status":"COMPLETED","enrollment_count":3404,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT05576207","title":"BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3390,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT05942924","title":"The NEU-STIM Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":3280,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT05114096","title":"Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":3254,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT04002908","title":"Low-birthweight Infant Feeding Exploration","phase":"","overall_status":"COMPLETED","enrollment_count":3188,"lead_sponsor_name":"Harvard School of Public Health (HSPH)","has_results":true},{"nct_id":"NCT05934318","title":"L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":2960,"lead_sponsor_name":"Liverpool School of Tropical Medicine","has_results":false},{"nct_id":"NCT06234332","title":"Peking University Birth Cohort in Weifang (PKUBC-WF)","phase":"","overall_status":"RECRUITING","enrollment_count":2800,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT05243901","title":"EPIPAGE 2 - 10-year Follow-up (RECONAI PROJECT)","phase":"","overall_status":"COMPLETED","enrollment_count":2383,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT02640638","title":"A RCT of CenteringPregnancy on Birth Outcomes","phase":"NA","overall_status":"COMPLETED","enrollment_count":2350,"lead_sponsor_name":"Clemson University","has_results":false},{"nct_id":"NCT07045844","title":"Effects of Enteral Feeding Regimens on NEC, Mortality, and Neurodevelopment in Very Preterm Infants","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2324,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT02811432","title":"Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa","phase":"NA","overall_status":"COMPLETED","enrollment_count":2221,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":true},{"nct_id":"NCT07143825","title":"A National Multicenter Survey on Small Vulnerable Newborns","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06414655","title":"Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT07015203","title":"The Combined First Trimester Screening","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Institute of Health Information and Statistics of the Czech Republic","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}